Keywords: Sanofi-Aventis, FDA, oxaliplatin, Eloxatin, colorectal cancer,

US FDA suspends generic oxaliplatin after legal action from Sanofi-Aventis

Article | 18 August 2009

Print This

French drug major Sanofi-Aventis says that a US appeals court has suspended approvals of generic copies of its colorectal cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in